2025
SJR Q2
JCR Q2 · 3,1
OA
14 matched articles
SCIE
Journal detail
International Journal of Hypertension
- Publisher
- John Wiley and Sons Ltd
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
2090038420900392
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,598
- Quartile Q2
- H-Index 54
- Cites/doc 3,71
- Docs (3y) 77
- Cites (3y) 190
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 3,1
- 5Y JIF 2,4
- JCI 0,45
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Internal Medicine Q2
Areas
- Medicine
WoS categories
- Peripheral Vascular Diseases
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q2 | 0,598 | 3,1 | 2,4 | 0,45 | Q3 | 54 |
| 2024 | Q2 | Q3 | 0,602 | 1,7 | 2 | 0,42 | Q3 | 51 |
| 2023 | Q3 | Q3 | 0,482 | 1,9 | 2,1 | 0,39 | Q3 | 51 |
| 2022 | Q3 | Q4 | 0,464 | 1,9 | 2,5 | 0,41 | Q3 | 51 |
| 2021 | Q2 | Q3 | 0,604 | 2,4 | 2,9 | 0,43 | Q3 | 51 |
| 2020 | Q2 | Q3 | 0,744 | 2,4 | 2,8 | 0,43 | Q3 | 51 |
| 2019 | Q3 | Q4 | 0,563 | 1,1 | — | 0,31 | Q4 | 51 |
| 2018 | — | Q3 | — | 1,9 | — | 0,38 | Q3 | — |
| 2017 | Q2 | Q3 | 0,578 | 1,6 | — | 0,37 | Q4 | 51 |
| 2016 | Q2 | — | 0,793 | — | — | — | — | 51 |
| 2015 | Q2 | — | 0,858 | — | — | — | — | 51 |
| 2014 | Q2 | — | 0,817 | — | — | — | — | 51 |
| 2013 | Q2 | — | 0,749 | — | — | — | — | 51 |
| 2012 | Q2 | — | 0,582 | — | — | — | — | 51 |
| 2011 | Q2 | — | 0,313 | — | — | — | — | 51 |
| 2010 | — | — | — | — | — | — | — | 51 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q3 | 36/100 |
| 2024 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 68/98 |
| 2023 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 57/96 |
| 2022 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | Q3 | 52/68 |
| 2021 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 49/67 |
| 2020 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 45/65 |
| 2019 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | Q4 | 61/65 |
| 2018 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 45/65 |
| 2017 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q4 | 48/65 |